Precigen Inc. (NASDAQ: PGEN) announced that the Centers for Medicare & Medicaid Services has assigned a permanent J‑code, J3404, to its approved therapy Papzimeos. The code became effective on April 1, 2026, simplifying reimbursement for community practices and removing billing friction for the treatment of recurrent respiratory papillomatosis (RRP).
The company said it has seen robust uptake of Papzimeos since its August 2025 launch, with patient‑hub enrollment exceeding 300. Precigen now projects first‑quarter 2026 revenue to exceed $18 million, a sharp increase from the $3.4 million in Q4 2025 net product sales. The forecast, while strong, falls short of the FactSet consensus estimate of $20.8 million, a factor that helped explain the 5.48% decline in the stock price following the announcement.
Precigen’s Q4 2025 results showed a net product revenue of $4.57 million, below the analyst estimate of $8.29 million, but the company’s EPS beat expectations by $0.01, driven by disciplined cost control and the absence of one‑time charges. The company’s cash position at year‑end 2025 was $100.4 million, providing a runway to reach the cash‑flow breakeven target set for the end of 2026.
The J‑code assignment is a key regulatory milestone that is expected to accelerate adoption and drive the projected revenue growth for the year. Management highlighted that the permanent J‑code removes a major barrier to market penetration and supports the company’s goal of achieving cash‑flow breakeven by the end of 2026. The company’s CFO noted that the 2025 net loss of $429.6 million reflects heavy investment in commercialization, but the growing revenue stream is expected to offset the burn as the product scales.
Market reaction to the announcement was tempered by the fact that the Q1 2026 revenue projection fell short of analyst consensus. Investors weighed the positive regulatory development against the lower‑than‑expected guidance and the company’s ongoing net loss, leading to a modest decline in the stock price. The market’s focus on the revenue forecast and cash‑burn trajectory underscores the importance of meeting or exceeding consensus estimates to maintain investor confidence.
The announcement also signals a strategic shift for Precigen from a research‑stage to a commercial‑stage company. The company’s first commercial product revenue of $9.7 million in 2025, up 149% from $3.9 million in 2024, demonstrates the commercial potential of Papzimeos and sets the stage for future growth in both adult and pediatric RRP markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.